11 terminated. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Terminated 11 |
| Phase 2 | 3 | Terminated 3 |
Follow Deglutition Disorders: new trials by email Literature Review of Deglutition Disorders trials Research Report on Deglutition Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF Intravenous Ketorolac, Intravenous Dexamethasone, Placebo - Dysphagia, Dysphonia | Phase 3 | Terminated | University of Nebraska | 33 | 2021-01-02 | 2024-08-23 |
| Efficacy and Safety of DLBS2411 in the Management of GERD Omeprazole, DLBS2411, Placebo capsule of Omeprazole - Gastroesophageal Reflux Disease (GERD) | Phase 3 | Terminated | Dexa Medica Group | 32 | 2018-08-16 | 2021-01-07 |
| A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) IW-3718, placebo, Standard-dose PPIs QD - Gastroesophageal Reflux Disease (GERD) | Phase 3 | Terminated | Ironwood Pharmaceuticals, Inc. | 495 | 2018-06-20 | 2021-08-19 |
| Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease Adrabetadex - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Terminated | Mandos LLC | 66 | 2015-12-23 | 2023-08-29 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| Evaluation of Transcutaneous Electrical Stimulation in Post Stroke Dysphagia Urostim I stimulation - Oropharyngeal Dysphagia, Deglutition Disorders | Phase 3 | Terminated | University Hospital, Rouen | 2 | 2014-06-01 | 2016-08-17 |
| Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients Compound Sodium Alginate Oral Suspension sachet, Matched placebo - Gastro-esophageal Reflux Disease (GERD) | Phase 3 | Terminated | Reckitt Benckiser Healthcare (UK) Limited | 16 | 2014-04-01 | 2017-10-06 |
| Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment Transoral Incisionless Fundoplication, Proton Pump Inhibitors; active control - Gastroesophageal Reflux Disease (GERD) | Phase 3 | Terminated | University of Pittsburgh | 60 | 2009-03-01 | 2018-03-30 |
| Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin - Acute Coronary Syndrome, Myocardial Infarction | Phase 3 | Terminated | Cogentus Pharmaceuticals | 5000 | 2007-12-01 | 2009-01-28 |
| Elucidation of Acid-Induced Pulmonary Inflammation lansoprazole, placebo - Gastroesophageal Reflux, Asthma | Phase 2 / Phase 3 | Terminated | University of Utah | 17 | 2006-08-01 | 2016-08-05 |
| Randomized Study of Two Interventions for Liquid Aspiration: Short-Term and Long-Term Effects Chin-down position, Thickened liquid administration - Pneumonia, Aspiration | Phase 3 | Terminated | National Institute on Deafness and Other Communication Disorders (NIDCD) | 600 | 2006-04-24 |
Gastroesophageal Reflux (6) · Peripheral Vascular Diseases (2) · Acute Coronary Syndrome (1) · Asthma (1) · CREST Syndrome (1) · Cerebrovascular Disorders (1) · Cognitive Dysfunction (1) · Coronary Artery Disease (1) · Coronary Thrombosis (1) · Dementia (1) · Disease (1) · Duodenal Obstruction (1) · Duodenal Ulcer (1) · Dyspepsia (1)
Digestive System Diseases (11) · Esophageal Diseases (11) · Gastrointestinal Diseases (11) · Esophageal Motility Disorders (7) · Nervous System Diseases (4) · Otorhinolaryngologic Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Pharyngeal Diseases (4) · Signs and Symptoms (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Respiratory Tract Diseases (3) · Cardiovascular Diseases (2) · Embolism and Thrombosis (2)
Omeprazole (3) · Lansoprazole (2) · 2-Hydroxypropyl-beta-cyclodextrin (1) · 4-nitro-3-dimethylaminopropiophenone (1) · Aspirin (1) · Clopidogrel (1) · Cyclodextrins (1) · Esomeprazole (1) · Pantoprazole (1) · Proton Pump Inhibitors (1) · Rabeprazole (1)
Cogentus Pharmaceuticals (1) · Dexa Medica Group (1) · Ironwood Pharmaceuticals, Inc. (1) · Jose Soberon, MD (1) · Mandos LLC (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Reckitt Benckiser Healthcare (UK) Limited (1) · University Hospital, Rouen (1) · University of Nebraska (1) · University of Pittsburgh (1) · University of Utah (1)
United States (7) · France (3) · Australia (2) · Canada (2) · Germany (2) · Bulgaria (1) · Chile (1) · China (1) · Czechia (1) · Hungary (1) · Indonesia (1) · Italy (1) · Mexico (1) · Netherlands (1) · New Zealand (1)
Blair A Jobe, MD (1) · Dadang Makmun, SpPD, KGEH (1) · Dolvy Girawan, M. Kes., SpPD, KGEH (1) · Dr. Jeri Logemann (1) · Dr. Joanne Robbins (1) · Hery D. Purnomo, SpPD, KGEH (1) · Iswan A. Nusi, Prof. KGEH, FINASIM, FACG (1) · Jose Soberon, MD (1) · Kathryn Peterson, MD (1) · Kevin Garvin, MD (1) · Mike Shetzline, MD, PhD (1) · Nicole D Bouvy, MD, PhD (1) · Pablo Lapuerta, MD (1)
PMID 18378947, PMID 20925534, PMID 27012778
2015 (1), U01DC003206 (1)